Peer-reviewed Oncology & Cancer Research Journal


Oncotarget is indexed/archived on


On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.
Learn more.


  • PubMed
  • PubMed Central
  • Scopus
  • META (Chan Zuckerberg Initiative) (2018-2022). META database was discontinued in 2022.
  • Dimensions (Digital Science)

Andrew V. Schally, a member of the Editorial Board of Oncotarget, a Nobel Prize winner in Physiology or Medicine: “Oncotarget is an outstanding and most important journal in the field of oncology and cancer research. Oncotarget is performing an extremely useful function for those of us working not only in cancer research, but also on other important topics in the field of medicine. Oncotarget deserves a strong support from investigators working in the area of oncology as well as from NIH.”

As stated by MEDLINE reviewers on 6/22/2017,
"This journal continues to play a major role in the publication of important basic science research papers. Editorial practices are consistently high. Ethical guidelines are consistently followed. This is an important research journal for the field."

Web of Science Update »

The Story Behind Oncotarget »

Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC